Status:
COMPLETED
Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Esophageal Cancer
Gastroesophageal Junction Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to describe the real-world effectiveness and patterns of use of adjuvant nivolumab in adult participants with Stage II/III Esophageal Cancer/Gastroesophageal Junction Canc...
Eligibility Criteria
Inclusion
- Participants aged 18 years or older at the index date
- All patients must have Stage II or Stage III carcinoma of the esophagus or gastroesophageal junction and have histologically or cytologically confirmed predominant adenocarcinoma or squamous cell carcinoma esophageal or gastroesophageal junction cancer at the time of initial diagnosis.
- Participants initiated nivolumab in adjuvant Esophageal Cancer (EC) or gastroesophageal junction cancer (GEJC) treatment within the index window.
Exclusion
- Participation in a clinical trial of an investigational drug concurrently during the adjuvant nivolumab treatment.
- From the date of diagnosis of EC or GJEC to data end period, patients were diagnosed with a primary diagnosis of a cancer other than EC or GJEC that requires systemic or other treatment
Key Trial Info
Start Date :
December 3 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 16 2025
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT06499298
Start Date
December 3 2024
End Date
April 16 2025
Last Update
May 31 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution - 0001
Shanghai, China, 200030